Tian Kai-Jiang, Yang Yu, Chen Guo-Shuai, Deng Nian-Hua, Tian Zhen, Bai Rui, Zhang Fan, Jiang Zhi-Sheng
Pathology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, China.
Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Institute of Cardiovascular Disease, University of South China, Hengyang, 421001, China.
Mol Cell Biochem. 2025 Apr;480(4):2077-2102. doi: 10.1007/s11010-024-05139-1. Epub 2024 Oct 24.
Atherosclerosis (AS) is a chronic inflammatory disease characterized by lipid deposition within the arterial intima, as well as fibrous tissue proliferation and calcification. AS has long been recognized as one of the primary pathological foundations of cardiovascular diseases in humans. Its pathogenesis is intricate and not yet fully elucidated. Studies have shown that AS is associated with oxidative stress, inflammatory response, lipid deposition, and changes in cell phenotype. Unfortunately, there is currently no effective prevention or targeted treatment for AS. The rapid advancement of omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, has opened up novel avenues to elucidate the fundamental pathophysiology and associated mechanisms of AS. Here, we review articles published over the past decade and focus on the current status, challenges, limitations, and prospects of omics in AS research and clinical practice. Emphasizing potential targets based on omics technologies will improve our understanding of this pathological condition and assist in the development of potential therapeutic approaches for AS-related diseases.
动脉粥样硬化（AS）是一种慢性炎症性疾病，其特征在于动脉内膜内的脂质沉积以及纤维组织增生和钙化。长期以来，AS一直被认为是人类心血管疾病的主要病理基础之一。其发病机制错综复杂，尚未完全阐明。研究表明，AS与氧化应激、炎症反应、脂质沉积以及细胞表型变化有关。不幸的是，目前尚无针对AS的有效预防措施或靶向治疗方法。包括基因组学、转录组学、蛋白质组学和代谢组学在内的组学技术的迅速发展，为阐明AS的基本病理生理学和相关机制开辟了新途径。在此，我们回顾过去十年发表的文章，并重点关注组学在AS研究和临床实践中的现状、挑战、局限性和前景。基于组学技术强调潜在靶点将增进我们对这种病理状况的理解，并有助于开发针对AS相关疾病的潜在治疗方法。
